{"DataElement":{"publicId":"2433","version":"5","preferredName":"Gleason Combined Pattern Score","preferredDefinition":"The Gleason score that provides a reproducible description of the glandular architecture of prostate tissue depending primarily on the microscopic patterns of cancerous glands and cell morphology.","longName":"GLEASO_COMB_PATT_SC","context":"NCI Standards","contextVersion":"1","DataElementConcept":{"publicId":"2189072","version":"1","preferredName":"Gleason Score Combined Pattern","preferredDefinition":"Information related to Gleason score combined pattern._The score derived from universally embraced prostate cancer grading system developed by Dr. Donald F. Gleason in 1977. The system provides a reproducible description of the glandular architecture of prostate tissue to which a pathologist assigns a score depending primarily on the microscopic patterns of cancerous glands and cell morphology. The system correlates well with behavior at the extremes: Gleason 1+1 tumors are the most well differentiated, slowly growing and rarely spread; Gleason 4+5 tumors are the most poorly differentiated, often widely metastatic at the time of diagnosis. In the commoner intermediate grade tumors, however, behavior is extremely variable.","longName":"GLEASO_COMB_PATT","context":"NCI Standards","contextVersion":"1","ObjectClass":{"publicId":"2547908","version":"1","preferredName":"Gleason Score for Prostate Cancer","preferredDefinition":"The score derived from universally embraced prostate cancer grading system developed by Dr. Donald F. Gleason in 1977. The system provides a reproducible description of the glandular architecture of prostate tissue to which a pathologist assigns a score depending primarily on the microscopic patterns of cancerous glands and cell morphology. The system correlates well with behavior at the extremes: Gleason 1+1 tumors are the most well differentiated, slowly growing and rarely spread; Gleason 4+5 tumors are the most poorly differentiated, often widely metastatic at the time of diagnosis. In the commoner intermediate grade tumors, however, behavior is extremely variable.","longName":"C28084","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gleason Score for Prostate Cancer","conceptCode":"C28084","definition":"The score derived from universally embraced prostate cancer grading system developed by Dr. Donald F. Gleason in 1977. The system provides a reproducible description of the glandular architecture of prostate tissue to which a pathologist assigns a score depending primarily on the microscopic patterns of cancerous glands and cell morphology. The system correlates well with behavior at the extremes: Gleason 1+1 tumors are the most well differentiated, slowly growing and rarely spread; Gleason 4+5 tumors are the most poorly differentiated, often widely metastatic at the time of diagnosis. In the commoner intermediate grade tumors, however, behavior is extremely variable.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"23681B08-081C-19C0-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-11-29","endDate":null,"createdBy":"MAESKEB","dateCreated":"2006-11-29","modifiedBy":"SBREXT","dateModified":"2017-08-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2207771","version":"1","preferredName":"Combined Pattern","preferredDefinition":"Made or joined or united into one or involving the joint activity of two or more.:Pattern; anything characterized by repetition.","longName":"C25454:C25336","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Combined","conceptCode":"C25454","definition":"Made or joined or united into one or involving the joint activity of two or more.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Pattern","conceptCode":"C25336","definition":"An arrangement of objects, facts, behaviors, or other things which have scientific, mathematical, geometric, statistical, or other meaning.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0429-2FC8-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"ONEDATA","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"E5E10A9E-4D23-4E03-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-10-07","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-10-07","modifiedBy":"TAYLORT","dateModified":"2017-08-08","changeDescription":"8/8/17 tt Transferred context, replaced NCI Gloss term with NCIt, added CSI and reg status per Round 5 finalization task.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2015237","version":"4","preferredName":"Gleason Score","preferredDefinition":"The score derived from universally embraced prostate cancer grading system developed by Dr. Donald F. Gleason in 1977. The system provides a reproducible description of the glandular architecture of prostate tissue to which a pathologist assigns a score depending primarily on the microscopic patterns of cancerous glands and cell morphology. The system correlates well with behavior at the extremes: Gleason 1+1 tumors are the most well differentiated, slowly growing and rarely spread; Gleason 4+5 tumors are the most poorly differentiated, often widely metastatic at the time of diagnosis. In the commoner intermediate grade tumors, however, behavior is extremely variable._A number or range of numeric values measuring performance, function, quality, or ability.","longName":"2015237v4.0","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"NUMBER","minLength":"1","maxLength":"2","minValue":null,"maxValue":null,"decimalPlace":"0","PermissibleValues":[{"value":"10","valueDescription":"Gleason Score 10 ","ValueMeaning":{"publicId":"5918377","version":"1","preferredName":"Gleason Score 10 ","longName":"5918377","preferredDefinition":"A Gleason score that indicates a highly aggressive prostatic adenocarcinoma. The score or sum is estimated by adding the most prevalent and the second most prevalent histopathologic pattern of the malignant infiltrate.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gleason Score 10","conceptCode":"C28094","definition":"A Gleason score that indicates a highly aggressive prostatic adenocarcinoma. The score or sum is estimated by adding the most prevalent and the second most prevalent histopathologic pattern of the malignant infiltrate.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5641149B-B351-5B37-E053-F662850A95C2","latestVersionIndicator":"Yes","beginDate":"2017-08-08","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2017-08-08","modifiedBy":"TAYLORT","dateModified":"2017-08-08","changeDescription":"Updated to correct concept. mc 2/13/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5641149B-B36B-5B37-E053-F662850A95C2","beginDate":"2002-02-11","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2017-08-08","modifiedBy":"ONEDATA","dateModified":"2017-08-08","deletedIndicator":"No"},{"value":"3","valueDescription":"Gleason Score 3 ","ValueMeaning":{"publicId":"5918384","version":"1","preferredName":"Gleason Score 3 ","longName":"5918384","preferredDefinition":"A Gleason score that is exceptionally assigned and indicates a low-grade prostatic adenocarcinoma. The score or sum is estimated by adding the most prevalent and the second most prevalent histopathologic pattern of the malignant infiltrate.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gleason Score 3","conceptCode":"C28096","definition":"A Gleason score that is exceptionally assigned and indicates a low-grade prostatic adenocarcinoma. The score or sum is estimated by adding the most prevalent and the second most prevalent histopathologic pattern of the malignant infiltrate.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"56435516-4DBB-1BCA-E053-F662850AE97A","latestVersionIndicator":"Yes","beginDate":"2017-08-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-08-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"56435516-4DD4-1BCA-E053-F662850AE97A","beginDate":"2002-02-11","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-08-08","modifiedBy":"ONEDATA","dateModified":"2017-08-08","deletedIndicator":"No"},{"value":"9","valueDescription":"Gleason Score 9 ","ValueMeaning":{"publicId":"5918382","version":"1","preferredName":"Gleason Score 9 ","longName":"5918382","preferredDefinition":"A Gleason score that indicates a high-grade prostatic adenocarcinoma. The score or sum is estimated by adding the most prevalent and the second most prevalent histopathologic pattern of the malignant infiltrate.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gleason Score 9","conceptCode":"C28093","definition":"A Gleason score that indicates a high-grade prostatic adenocarcinoma. The score or sum is estimated by adding the most prevalent and the second most prevalent histopathologic pattern of the malignant infiltrate.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"56435516-4D6E-1BCA-E053-F662850AE97A","latestVersionIndicator":"Yes","beginDate":"2017-08-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-08-08","modifiedBy":"TAYLORT","dateModified":"2017-08-08","changeDescription":"Updated to correct concept. mc 2/13/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"56435516-4D88-1BCA-E053-F662850AE97A","beginDate":"2002-02-11","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-08-08","modifiedBy":"ONEDATA","dateModified":"2017-08-08","deletedIndicator":"No"},{"value":"4","valueDescription":"Gleason Score 4","ValueMeaning":{"publicId":"5918385","version":"1","preferredName":"Gleason Score 4","longName":"5918385","preferredDefinition":"A Gleason score that is relatively uncommon and indicates a low-grade prostatic adenocarcinoma. The score or sum is estimated by adding the most prevalent and the second most prevalent histopathologic pattern of the malignant infiltrate.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gleason Score 4","conceptCode":"C28097","definition":"A Gleason score that is relatively uncommon and indicates a low-grade prostatic adenocarcinoma. The score or sum is estimated by adding the most prevalent and the second most prevalent histopathologic pattern of the malignant infiltrate.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"56435516-4DE1-1BCA-E053-F662850AE97A","latestVersionIndicator":"Yes","beginDate":"2017-08-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-08-08","modifiedBy":"TAYLORT","dateModified":"2017-08-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"56435516-4DFA-1BCA-E053-F662850AE97A","beginDate":"2002-02-11","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-08-08","modifiedBy":"ONEDATA","dateModified":"2017-08-08","deletedIndicator":"No"},{"value":"5","valueDescription":"Gleason Score 5 ","ValueMeaning":{"publicId":"5918386","version":"1","preferredName":"Gleason Score 5 ","longName":"5918386","preferredDefinition":"An exceptionally uncommon Gleason score that indicates a less aggressive prostatic adenocarcinoma. The score or sum is estimated by adding the most prevalent and the second most prevalent histopathologic pattern of the malignant infiltrate.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gleason Score 5","conceptCode":"C28098","definition":"An exceptionally uncommon Gleason score that indicates a less aggressive prostatic adenocarcinoma. The score or sum is estimated by adding the most prevalent and the second most prevalent histopathologic pattern of the malignant infiltrate.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"56435516-4E07-1BCA-E053-F662850AE97A","latestVersionIndicator":"Yes","beginDate":"2017-08-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-08-08","modifiedBy":"TAYLORT","dateModified":"2017-08-08","changeDescription":"Updated to correct concept. mc 2/13/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"56435516-4E21-1BCA-E053-F662850AE97A","beginDate":"2002-02-11","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-08-08","modifiedBy":"ONEDATA","dateModified":"2017-08-08","deletedIndicator":"No"},{"value":"6","valueDescription":"Gleason Score 6 ","ValueMeaning":{"publicId":"5918387","version":"1","preferredName":"Gleason Score 6 ","longName":"5918387","preferredDefinition":"A Gleason score that indicates a low-grade prostatic adenocarcinoma. The score or sum is estimated by adding the most prevalent and the second most prevalent histopathologic pattern of the malignant infiltrate.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gleason Score 6","conceptCode":"C28090","definition":"A Gleason score that indicates a low-grade prostatic adenocarcinoma. The score or sum is estimated by adding the most prevalent and the second most prevalent histopathologic pattern of the malignant infiltrate.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"56435516-4E2E-1BCA-E053-F662850AE97A","latestVersionIndicator":"Yes","beginDate":"2017-08-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-08-08","modifiedBy":"TAYLORT","dateModified":"2017-08-08","changeDescription":"Updated to correct concept. mc 2/13/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"56435516-4E48-1BCA-E053-F662850AE97A","beginDate":"2002-02-11","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-08-08","modifiedBy":"ONEDATA","dateModified":"2017-08-08","deletedIndicator":"No"},{"value":"7","valueDescription":"Gleason Score 7 ","ValueMeaning":{"publicId":"5918388","version":"1","preferredName":"Gleason Score 7 ","longName":"5918388","preferredDefinition":"A Gleason score that indicates an intermediate-grade prostatic adenocarcinoma. The score or sum is estimated by adding the most prevalent and the second most prevalent histopathologic pattern of the malignant infiltrate.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gleason Score 7","conceptCode":"C28091","definition":"A Gleason score that indicates an intermediate-grade prostatic adenocarcinoma. The score or sum is estimated by adding the most prevalent and the second most prevalent histopathologic pattern of the malignant infiltrate.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"56435516-4E55-1BCA-E053-F662850AE97A","latestVersionIndicator":"Yes","beginDate":"2017-08-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-08-08","modifiedBy":"TAYLORT","dateModified":"2017-08-08","changeDescription":"Updated to correct concept. mc 2/13/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"56435516-4E6F-1BCA-E053-F662850AE97A","beginDate":"2002-02-11","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-08-08","modifiedBy":"ONEDATA","dateModified":"2017-08-08","deletedIndicator":"No"},{"value":"8","valueDescription":"Gleason Score 8 ","ValueMeaning":{"publicId":"5918389","version":"1","preferredName":"Gleason Score 8 ","longName":"5918389","preferredDefinition":"A Gleason score that indicates a histologically aggressive prostatic adenocarcinoma. The score or sum is estimated by adding the most prevalent and the second most prevalent histopathologic pattern of the malignant infiltrate.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gleason Score 8","conceptCode":"C28092","definition":"A Gleason score that indicates a histologically aggressive prostatic adenocarcinoma. The score or sum is estimated by adding the most prevalent and the second most prevalent histopathologic pattern of the malignant infiltrate.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"56435516-4E7C-1BCA-E053-F662850AE97A","latestVersionIndicator":"Yes","beginDate":"2017-08-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-08-08","modifiedBy":"TAYLORT","dateModified":"2017-08-08","changeDescription":"Updated to correct concept. mc 2/13/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"56435516-4E96-1BCA-E053-F662850AE97A","beginDate":"2002-02-11","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-08-08","modifiedBy":"ONEDATA","dateModified":"2017-08-08","deletedIndicator":"No"},{"value":"2","valueDescription":"Gleason Score 2","ValueMeaning":{"publicId":"5918390","version":"1","preferredName":"Gleason Score 2","longName":"5918390","preferredDefinition":"A low Gleason score that is exceptionally uncommon and indicates a low-grade, non-aggressive prostatic adenocarcinoma. The score or sum is estimated by adding the most prevalent and the second most prevalent histopathologic pattern of the malignant infiltrate.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gleason Score 2","conceptCode":"C28095","definition":"A low Gleason score that is exceptionally uncommon and indicates a low-grade, non-aggressive prostatic adenocarcinoma. The score or sum is estimated by adding the most prevalent and the second most prevalent histopathologic pattern of the malignant infiltrate.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"564361CC-31D1-28D1-E053-F662850A64B0","latestVersionIndicator":"Yes","beginDate":"2017-08-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-08-08","modifiedBy":"ONEDATA","dateModified":"2017-08-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"564361CC-31EA-28D1-E053-F662850A64B0","beginDate":"2002-02-11","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-08-08","modifiedBy":"ONEDATA","dateModified":"2017-08-08","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"5918402","version":"1","preferredName":"Gleason Score for Prostate Cancer Score","preferredDefinition":"A system of grading prostate cancer tissue based on how it looks under a microscope. Gleason scores range from 2 to 10 and indicate how likely it is that a tumor will spread. A low Gleason score means the cancer tissue is similar to normal prostate tissue and the tumor is less likely to spread; a high Gleason score means the cancer tissue is very different from normal and the tumor is more likely to spread.:A number or range of numeric values measuring performance, function, quality, or ability.","longName":"C28084:C25338","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gleason Score for Prostate Cancer","conceptCode":"C28084","definition":"The score derived from universally embraced prostate cancer grading system developed by Dr. Donald F. Gleason in 1977. The system provides a reproducible description of the glandular architecture of prostate tissue to which a pathologist assigns a score depending primarily on the microscopic patterns of cancerous glands and cell morphology. The system correlates well with behavior at the extremes: Gleason 1+1 tumors are the most well differentiated, slowly growing and rarely spread; Gleason 4+5 tumors are the most poorly differentiated, often widely metastatic at the time of diagnosis. In the commoner intermediate grade tumors, however, behavior is extremely variable.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Score","conceptCode":"C25338","definition":"A number or range of numeric values measuring performance, function, quality, or ability.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"56435B98-052D-2101-E053-F662850A10FF","latestVersionIndicator":"Yes","beginDate":"2017-08-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-08-08","modifiedBy":"ONEDATA","dateModified":"2017-08-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"56416639-FBC6-1D78-E053-F662850AD6D9","latestVersionIndicator":"Yes","beginDate":"2004-05-17","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2017-08-08","modifiedBy":"COOPERM","dateModified":"2017-12-04","changeDescription":"8/23/17 tt released DN VD. 8/8/17 tt VD versioned for change to rep term, qualifier, def, long name; added CSI and reg status, transferred context per Round 5 finalization task.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008587","version":"2","longName":"Type of Disease","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811910","version":"1","longName":"Prostate","context":"CTEP"}]},{"publicId":"2008589","version":"2","longName":"Type of Category","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811953","version":"1","longName":"Disease Description","context":"CTEP"}]},{"publicId":"2008594","version":"2.31","longName":"Trial Type Usages (CDE Disease Committees)","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811916","version":"1","longName":"Localized Prostate","context":"CTEP"},{"publicId":"2811920","version":"1","longName":"Non-local Prostate","context":"CTEP"},{"publicId":"2811937","version":"1","longName":"Pathology Prostate","context":"CTEP"}]},{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811685","version":"1","longName":"CCR","context":"CCR"}]},{"publicId":"2182125","version":"1","longName":"CCR Implementation","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811673","version":"1","longName":"C3D","context":"CCR"}]},{"publicId":"2192345","version":"1","longName":"Data Standards","context":"NCIP","ClassificationSchemeItems":[{"publicId":"2859963","version":"1","longName":"Standard CRFs","context":"NCIP"},{"publicId":"3914492","version":"1","longName":"Diagnosis Gross Tumor CRF","context":"NCIP"}]},{"publicId":"2193113","version":"1","longName":"Division of Cancer Epidemiology and Genetics","context":"PS-CC","ClassificationSchemeItems":[{"publicId":"2812078","version":"1","longName":"CGEMS","context":"PS-CC"}]},{"publicId":"2194255","version":"1","longName":"Type of Condition","context":"DCP","ClassificationSchemeItems":[{"publicId":"2812151","version":"1","longName":"Prostate - Lycopene","context":"DCP"}]},{"publicId":"4057943","version":"1","longName":"Disease Site","context":"NRG","ClassificationSchemeItems":[{"publicId":"4171065","version":"1","longName":"RTOG-0924","context":"NRG"},{"publicId":"4171064","version":"1","longName":"RTOG-0815","context":"NRG"},{"publicId":"4171063","version":"1","longName":"RTOG-0534","context":"NRG"}]},{"publicId":"5635300","version":"1","longName":"Case Report Form (CRF) Modules","context":"NCI Standards","ClassificationSchemeItems":[{"publicId":"5915896","version":"1","longName":"Gross Pathology","context":"NCI Standards"}]},{"publicId":"6601273","version":"1","longName":"CPTAC (Clinical Proteomic Tumor Analysis Consortium)","context":"OCCPR","ClassificationSchemeItems":[{"publicId":"6779562","version":"1","longName":"PRAD Local Pathology","context":"OCCPR"},{"publicId":"6779563","version":"1","longName":"PRAD Pathology Review","context":"OCCPR"},{"publicId":"5635376","version":"1","longName":"Prostate","context":"OCCPR"},{"publicId":"6779561","version":"1","longName":"PRAD Baseline","context":"OCCPR"}]}],"AlternateNames":[{"name":"GLEASO_COMB_PATT_VAL","type":"C3D Name","context":"CCR"},{"name":"OCCPR","type":"USED_BY","context":"OCCPR"}],"ReferenceDocuments":[{"name":"COMMENT_127","type":"COMMENT","description":"Instruction on template form: (2-10 if primary and secondary patterns unavailable)","url":null,"context":"CTEP"},{"name":"Gleason score","type":"Preferred Question Text","description":"Gleason score","url":null,"context":"NCI Standards"},{"name":"CRF Text","type":"Alternate Question Text","description":"Gleason Score, Combined","url":null,"context":"CTEP"},{"name":"Source","type":"DATA_ELEMENT_SOURCE","description":"Gleason DF. Histologic grading of prostate cancer: a perspective. Human Pathology. 23(3):273-9, 1992.","url":null,"context":"CTEP"},{"name":"DCP Document Text 2","type":"Alternate Question Text","description":"Gleason Score","url":null,"context":"DCP"},{"name":"DCP Document Text","type":"Alternate Question Text","description":"GGS","url":null,"context":"DCP"},{"name":"CPTAC-PRAD-1","type":"Alternate Question Text","description":"Gleason Score","url":null,"context":"OCCPR"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Standard","id":"5643EB1B-EE04-1D44-E053-F662850A078C","latestVersionIndicator":"Yes","beginDate":"2004-05-17","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-08-08","modifiedBy":"COLBERTM","dateModified":"2021-11-16","changeDescription":"11/15/21 mr Removed MCL PCA prostate CSI.  8/23/17 tt released DN CDE. 8/8/17 tt CDE versioned due to new VD version, change to long name, short name, def, question text; transferred Context, added CSI and reg status per Round 5 finalization task.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}